Paper
The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C
Published Aug 1, 2012 · Emmanuel Thomas, Emmanuel Thomas, M. Ghany
Antiviral Chemistry and Chemotherapy
Q3 SJR score
122
Citations
4
Influential Citations
Abstract
Ribavirin has been used as an antiviral agent for several decades. Although it has activity against numerous viruses, its major use clinically has been in the treatment of respiratory syncytial virus in paediatric patients and chronic HCV infection in both children and adults. This review highlights the clinical application and mechanism of action of ribavirin and discusses the future role of ribavirin in treatment of HCV where there are intense research efforts to improve therapy.
Highly CitedStudy Snapshot
Ribavirin is a widely used antiviral agent for treating respiratory syncytial virus in children and chronic HCV infection in adults, with potential for future improvements in HCV therapy.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7
The TLR7 agonist ANA773 effectively reduces HCV RNA levels in chronic hepatitis C patients due to differences in the induction of endogenous interferons and IFN-stimulated gene products.
2012·27citations·A. Boonstra et al.·Antiviral Therapy
Antiviral Therapy
Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
Ribavirin enhances the anti-hepatitis C effects of interferon- by enhancing autocrine IFN- and enhancing IL-8 through activating AP-1.
2012·19citations·Yoshio Tokumoto et al.·The Journal of infectious diseases
The Journal of infectious diseases
The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
In genotype 1 HCV patients, adding ribavirin or ribavirin with Peg-IFN provides additive antiviral activity, leading to faster viral clearance.
2012·121citations·S. Zeuzem et al.·Hepatology
Hepatology
Update on alisporivir in treatment of viral hepatitis C
Alisporivir (ALV) is a once-daily, pangenotypic, and safe HTA that can improve the efficacy of pegylated IFN and ribavirin in treating viral hepatitis C, with potential for IFN-sparing combinations with
2012·49citations·R. Flisiak et al.·Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs
An orally available, small-molecule interferon inhibits viral replication
Orally available, small-molecule type I interferon receptor agonist effectively inhibits viral replication and shows potential as a potential interferon substitute for treating antiviral infections.
2012·45citations·H. Konishi et al.·Scientific Reports
Scientific Reports
Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta‐analysis
Erythropoietin administration in patients with anaemia during anti-HCV therapy significantly enhances sustained virological response compared to ribavirin dose reduction.
2012·19citations·S. Alavian et al.·Journal of Viral Hepatitis
Journal of Viral Hepatitis
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C
Ribavirin combined with interferon improves sustained virological response rates in chronic hepatitis C patients by 25-30%, potentially reducing viral breakthroughs and relapses.
2012·22citations·V. Clark et al.·Liver International
Liver International
Treatment of chronic hepatitis C – are interferons really necessary?
Chronic hepatitis C can be cured without interferon, with various compounds like PSI 7977, NS5a inhibitors, and cyclophillin antagonists showing promise.
2012·21citations·P. Ferenci·Liver International
Liver International
Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C
Erythropoietin (EPO) can improve quality of life and sustain optimal ribavirin dose in patients with viral genotype 1 anaemia during chronic hepatitis C therapy, but its evidence for other viral genotypes and conditions is insufficient.
2012·20citations·F. Stickel et al.·Journal of Viral Hepatitis
Journal of Viral Hepatitis
Citations
Thermal cycling-hyperthermia down-regulates liposaccharide-induced inflammation in human blood and helps with clearance of herpes simplex virus type 1
Thermal cycling-hyperthermia (TC-HT) effectively reduces inflammation and aids in herpes simplex virus type 1 clearance, outperforming traditional hyperthermia in safety and therapeutic effect.
2024·1citation·Yu-Yi Kuo et al.·bioRxiv
bioRxiv
Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis.
Remdesivir and Nirmatrelvir/Ritonavir show significant efficacy in reducing hospitalization and severe outcomes in COVID-19 patients, while Lopinavir/Ritonavir and Ivermectin show inconsistent results.
2024·0citations·Saeid Mezail Mawazi et al.·The American journal of emergency medicine
The American journal of emergency medicine
N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses
NHC/molnupiravir shows potential in inhibiting viral replication and neurological disease caused by orthobunyaviruses, potentially as a generalizable strategy for treating acute viral encephalitis.
2024·0citations·D. Ojha et al.·PLOS Pathogens
PLOS Pathogens
Recent advances in triazole synthesis via click chemistry and their pharmacological applications: A review.
Copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry has advanced in synthesizing biologically important triazole molecules, aiding in drug discovery and optimization processes.
2024·5citations·Riya Khandelwal et al.·Bioorganic & medicinal chemistry letters
Bioorganic & medicinal chemistry letters
Design, Synthesis, and In-vitro anti-tuberculosis activity of 2-substituted-1,5-diphenyl-1,2-dihydro-3H-1,2,4-triazole-3-thione Derivatives
2-substituted 1,5-diphenyl-1,2-dihydro-3H-1,2,4-triazole-3-thione derivatives show significant in vitro anti-tuberculosis activity, with morpholine-substituted derivatives showing greater affinity towards M. tub
2024·0citations·T. Venkatachalam et al.·Journal of Physics: Conference Series
Journal of Physics: Conference Series
Exploring Triazole-Based Drugs: Synthesis, Application, FDA Approvals, and Clinical Trial Updates - A Comprehensive Review
Triazole-based drugs show extensive therapeutic potential and have been successfully approved by the FDA for treating various conditions since 1981.
2024·7citations·Javed Khan et al.·Tetrahedron
Tetrahedron